Quartette Oral Contraceptive Now Available
Teva announced the launch of Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.
RELATED: Ob/Gyn Resource Center
Quartette features a 91-day oral regimen, where the dose of estrogen increases at three distinct points over the first 84 days and the amount of progestin remains consistent:
- 42 tablets containing levonorgestrel 150mcg + ethinyl estradiol 20mcg followed by,
- 21 tablets containing levonorgestrel 150mcg + ethinyl estradiol 25mcg followed by,
- 21 tablets containing levonorgestrel 150mcg + ethinyl estradiol 30mcg followed by,
- 7 tablets containing ethinyl estradiol 10mcg
Quartette is the only FDA-approved extended-regimen oral contraceptive that has an ascending dose of estrogen designed to induce four short, light periods per year.
Quartette was approved by the FDA on March 29th, 2013 based on data from clinical trials that demonstrated 97% effectiveness at preventing pregnancy. In addition, breakthrough bleeding and unscheduled spotting decreased over successive 91-day cycles.
Teva is offering a Quartette Savings Card that can be accessed at HerQuartette.com.
For more information call (888) TEVA-USA or visit HerQuartette.com.